Trending Now

US Pharma Co. Granted FDA Approval for IV Smallpox Drug

Streetwise Reports (05/20/2022)

SIGA Technologies Inc. shares traded 30% higher after the company reported that the U.S. FDA has granted approval for an intravenous (IV) formulation of its TPOXX® (tecovirimat) for use in treating smallpox.

Tags: Biotechnology / Pharmaceuticals

New Improved Drug Expected to Get FDA Approval Next Month

Research Report

(05/20/2022)

Greenlighting of its medication for urea cycle disorders is the first of a trio of catalysts anticipated for this U.S. pharma firm in 2022, noted a ROTH Capital Partners report. Streetwise reviews the newest updates in this drug development and the company's stock.

Tags: Biotechnology / Pharmaceuticals

EU Co. Secures Smallpox Vaccine Order to Target Monkeypox

Streetwise Reports (05/19/2022)

Shares of Danish vaccine company Bavarian Nordic A/S traded 70% higher after the company advised that it had secured a contract for its IMVANEX® smallpox vaccine from an undisclosed country in Europe for use in addressing newly confirmed cases of monkeypox.

Tags: Biotechnology / Pharmaceuticals

Firm Reports Encouraging Trial Results in Cystinosis

Research Report

(05/19/2022)

New data from a Wedbush report shows that study patients experienced improvements in visual-motor integration, motor coordination, and visual perception. Streetwise Reports takes a deeper look at Avrobio Inc.

Tags: Biotechnology / Pharmaceuticals

Coverage Launched on Co. in Alzheimer's Drug Space

Research Report

(05/17/2022)

This biopharma's therapeutic candidates for central nervous system diseases stand out because of their selective and specific mechanism of action, noted a Leede Jones Gable report.

Tags: Biotechnology / Pharmaceuticals

Clinical Catalysts for Biotech's Stock On Track for Mid 2022

Research Report

(05/15/2022)

Upcoming potential stock-moving events include new data concerning the company's lead therapeutic candidate for age-related eye diseases, noted a ROTH Capital Partners report.

Tags: Biotechnology / Pharmaceuticals

Biopharma Co. to Launch Two Clinical Trials This Year

Research Report

(05/14/2022)

Success in either program, atopic dermatitis or asthma, "could lead to multiblockbuster sales," noted a ROTH Capital Partners report.

Tags: Biotechnology / Pharmaceuticals

First Results From Biotech Co.'s Lymphoma Program Are Impressive

Research Report

(05/13/2022)

This data will be presented at the 2022 annual meeting of the European Hematology Association on June 11th, noted a ROTH Capital Partners report.

Tags: Biotechnology / Pharmaceuticals

Japan Pharma Co. Invests $275 Million in U.S. Oncology Firm

Streetwise Reports (05/13/2022)

Cullinan Oncology Inc. shares traded 23% higher yesterday after the company reported it entered into a strategic investment, development and licensing agreement with Taiho Pharmaceutical Co. Ltd. of Japan for its CLN-081/TAS6417 for use in treatment of non-small cell lung cancer.

Tags: Biotechnology / Pharmaceuticals

Pfizer Offers $11.6B to Buy Biopharma Co.

Streetwise Reports (05/10/2022)

Shares of Biohaven Pharmaceutical Holding Co. Ltd. traded almost 70% higher after the company reported it agreed to be acquired by Pfizer Inc. for $148.50 per share in cash plus future royalty opportunities.

Tags: Biotechnology / Pharmaceuticals

Ophthalmic Med Tech. Firm Sees 166% Gain in LAL Implants

Streetwise Reports (05/06/2022)

Shares of RxSight Inc. traded 7% higher after the company reported Q1/22 financial results which highlighted a 157% YoY increase in revenue and a 208% increase in unit sales of its Light Delivery Devices (LDD™s) utilized in cataract surgery procedures to implant its RxSight Light Adjustable Lens® (LAL), which it says is "the world's first and only adjustable intraocular lens (IOL) that is customized after cataract surgery."

Tags: Life Sciences Tools & DiagnosticsMedical Devices

Analyst Says Avivagen Is a Strong Buy

Contributed Opinion

Clive Maund (05/05/2022)

With Avivagen's breakthrough product relishing in its success, Analyst Clive Maund reviews if he believes it is now a formidable contender as a Buy.

Tags: NutraceuticalsBiotechnology / Pharmaceuticals

Biopharma Co. Licenses Orphan Drug to UK Firm for $450M

Streetwise Reports (05/05/2022)

Intercept Pharmaceuticals Inc. shares traded 20% higher after the company reported it entered into a $450 million licensing agreement with Advanz Pharma in markets outside of the U.S. for Ocaliva® for use in treatment of primary biliary cholangitis, a progressive and chronic autoimmune disease which affects the liver.

Tags: Biotechnology / Pharmaceuticals

Pilot Launch of VLN Cigarettes in Progress

Research Report

(05/03/2022)

These "very low nicotine" tobacco products will be an alternative for smokers when the FDA effects its imminent menthol cigarette ban, noted a ROTH Capital Partners report.

Tags: AgricultureBiotechnology / Pharmaceuticals

FDA Expands Use for Transcarotid Stent

Streetwise Reports (05/02/2022)

Silk Road Medical Inc. shares traded 12% higher after the company reported that the U.S. FDA granted expanded authorization for its ENROUTE® transcarotid stent system for use in preventing stroke in patients deemed to be at standard risk for adverse events from carotid endarterectomy.

Tags: Medical Devices

Expert Investing Ideas

"We are initiating coverage on PMN with a Speculative Buy rating."

–Douglas Loe, Leede Jones Gable

"RHT is rated an Immediate Buy here."

–Clive Maund, CliveMaund.com

"We view PMN's path to clinical value inflection favorably."

–Steve Silver, Argus Research

"AGN has reacted back satisfactorily to another good buy spot."

–Clive Maund, CliveMaund.com

"AGN's current valuation is favorable from a risk-reward standpoint."

–André Uddin, Research Capital Corporation

"As we can see on its latest six-month chart, AGN's stock has soared."

–Clive Maund, CliveMaund.com

"AGN has a lot of potential, and I placed my bet with shares bought."

–Bob Moriarty, 321 Gold

"After a 1 for 100 rollback, AGN has big upside potential."

–Clive Maund, CliveMaund.com

"AGN stock looks like it is in the process of turning up from a low."

–Clive Maund, CliveMaund.com

"We could soon see some good gains in AGN."

–Clive Maund, CliveMaund.com

"AGN's risk/reward profile is attractive."

–André Uddin, Research Capital Corporation

"RTG's vigorous uptrend is probably targeting the CA$1.30–1.40 area."

–Clive Maund, CliveMaund.com

"AGN is switching focus to the IPF/chronic cough indication."

–André Uddin, Research Capital Corporation

"AGN received positive FDA feedback on its planned Phase 1 trial."

–Sam Riches, Weekend Dispensary

"AGN requested a meeting with the FDA to discuss advancing ifenprodil."

–André Uddin, Research Capital Corporation

"Final results from AGN's Phase 2b COVID-19 trial are expected soon."

–André Uddin, Research Capital Corporation

"AGN is to continue a number of preclinical studies of DMT for stroke."

–André Uddin, Research Capital Corporation

"AGN is starting clinical research with a psychedelic drug for stroke."

–Clive Maund, CliveMaund.com

"The slight drop today [of RHT shares] on very low volume is interpreted as a sign that it is ready to turn higher again now or very soon, and it is therefore rated an immediate buy."

–Clive Maund, CliveMaund.com

"The least we can expect with AGN is a significant bounce from here."

–Clive Maund, CliveMaund.com

Company News

RHT:TSX.V; RQHTF:OTCQB; A2AJTB:WKN
5/19/2022 – Reliq Health Technologies, Inc. Announces Go Live in Two Clinical Trials, New Contracts in TX and FL

PMN:TSX; ARFXF:OTCQB
5/17/2022 – ProMIS Neurosciences presents at the 2022 Neuro4D International Conference

NASDAQ Biotech ARCA Pharmaceutical

Biotech Co. Advances COVID-19 Vaccines Toward Approval

Research Report

(05/01/2022)

They include booster vaccines for different age groups of children and an Omicron-targeting booster for adults, noted an H.C. Wainwright & Co. report.

Tags: Biotechnology / Pharmaceuticals

Is Reliq Health Technologies a Nutrimental 'Buy'?

Contributed Opinion

Clive Maund (04/29/2022)

After recovering from a short "character assassination," Reliq Health Technologies may be on the up-and-up. Clive Maund examines the latest data from the company to see if it would make a good 'buy'.

Tags: Life Sciences Tools & Diagnostics

Biopharma Co. Posts 32% YoY Gain in Proprietary Sales

Streetwise Reports (04/27/2022)

Alkermes Plc. shares traded 12% higher after the Ireland-based company reported Q1/22 financial results and reiterated its FY/22 business outlook.

Tags: Biotechnology / Pharmaceuticals

Could a New Prescription Drug Treat This Common Ailment?

Research Report

(04/27/2022)

The combination drug Halo-Lido is poised to be the first-of-its-kind prescription treatment approved by the U.S. Food and Drug Administration for this prevalent medical condition, noted a DawsonJames report.

Tags: Biotechnology / Pharmaceuticals

Biopharma Co. Posts Positive Data in Ph. 1 Cancer Trials

Streetwise Reports (04/25/2022)

Nkarta Inc. shares traded over 120% higher after the company reported positive dosing data from two separate Phase 1 clinical trials evaluating the use of natural killer cell therapies to target r/r acute myeloid leukemia and myelodysplastic syndrome and r/r B cell malignancies.

Tags: Biotechnology / PharmaceuticalsRegenerative Medicine

FDA Grants RMAT Status for T-Cell Therapy for Six Viruses

Streetwise Reports (04/20/2022)

Shares of AlloVir Inc. traded 18% higher after the firm reported that the U.S. FDA awarded Regenerative Medicine Advanced Therapy designation to its posoleucel for use in preventing life-threatening infections from six viruses in allogeneic hematopoietic cell transplant patients.

Tags: Biotechnology / PharmaceuticalsRegenerative Medicine

The Life Sciences Report

Trending Now

US Pharma Co. Granted FDA Approval for IV Smallpox Drug

New Improved Drug Expected to Get FDA Approval Next Month

EU Co. Secures Smallpox Vaccine Order to Target Monkeypox

Firm Reports Encouraging Trial Results in Cystinosis

Coverage Launched on Co. in Alzheimer's Drug Space

Clinical Catalysts for Biotech's Stock On Track for Mid 2022

Biopharma Co. to Launch Two Clinical Trials This Year

First Results From Biotech Co.'s Lymphoma Program Are Impressive

Japan Pharma Co. Invests $275 Million in U.S. Oncology Firm

Pfizer Offers $11.6B to Buy Biopharma Co.

Ophthalmic Med Tech. Firm Sees 166% Gain in LAL Implants

Analyst Says Avivagen Is a Strong Buy

Biopharma Co. Licenses Orphan Drug to UK Firm for $450M

Pilot Launch of VLN Cigarettes in Progress

FDA Expands Use for Transcarotid Stent

Expert Investing Ideas

Company News

Get Our Streetwise Reports Life Sciences Report Newsletter Free and be the first to know!

Biotech Co. Advances COVID-19 Vaccines Toward Approval

Is Reliq Health Technologies a Nutrimental 'Buy'?

Biopharma Co. Posts 32% YoY Gain in Proprietary Sales

Could a New Prescription Drug Treat This Common Ailment?

Biopharma Co. Posts Positive Data in Ph. 1 Cancer Trials

FDA Grants RMAT Status for T-Cell Therapy for Six Viruses

Enter a valid ticker symbol below or start typing for suggestions.